The Experts below are selected from a list of 24234 Experts worldwide ranked by ideXlab platform
Akos Somoskovi - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary tuberculosis due to Mycobacterium bovis subsp caprae in captive siberian tiger
Emerging Infectious Diseases, 2003Co-Authors: Ákos Lantos, Stefan Niemann, Endre Sós, Károly Erdélyi, Sándor Dávid, Linda M. Parsons, Tanja Kubica, László Mezõsi, Sabine Ruschgerdes, Akos SomoskoviAbstract:We report the first case of pulmonary tuberculosis caused by Mycobacterium bovis subsp. caprae in a captive Siberian tiger, an endangered feline. The pathogen was isolated from a tracheal aspirate obtained by bronchoscopy. This procedure provided a reliable in vivo diagnostic method in conjunction with conventional and molecular tests for the detection of mycobacteria.
-
Pulmonary Tuberculosis due to Mycobacterium bovis in Captive Siberian Tiger
Centers for Disease Control and Prevention, 2003Co-Authors: Ákos Lantos, Stefan Niemann, László Mezősi, Endre Sós, Károly Erdélyi, Sándor Dávid, Linda M. Parsons, Tanja Kubica, Sabine Rüsch-gerdes, Akos SomoskoviAbstract:We report the first case of pulmonary tuberculosis caused by Mycobacterium bovis subsp. caprae in a captive Siberian tiger, an endangered feline. The pathogen was isolated from a tracheal aspirate obtained by bronchoscopy. This procedure provided a reliable in vivo diagnostic method in conjunction with conventional and molecular tests for the detection of mycobacteria
Stephen V Gordon - One of the best experts on this subject based on the ideXlab platform.
-
updated reference genome sequence and annotation of Mycobacterium bovis af2122 97
Genome Announcements, 2017Co-Authors: Kerri M Malone, Damien Farrell, Tod Stuber, Olga T Schubert, Ruedi Aebersold, Suelee Robbeausterman, Stephen V GordonAbstract:ABSTRACT We report here an update to the reference genome sequence of the bovine tuberculosis bacillus Mycobacterium bovis AF2122/97, generated using an integrative multiomics approach. The update includes 42 new coding sequences (CDSs), 14 modified annotations, 26 single-nucleotide polymorphism (SNP) corrections, and disclosure that the RD900 locus, previously described as absent from the genome, is in fact present.
-
updated reference genome sequence and annotation of Mycobacterium bovis af2122 97
bioRxiv, 2017Co-Authors: Kerri M Malone, Damien Farrell, Tod Stuber, Olga T Schubert, Ruedi Aebersold, Suelee Robbeausterman, Stephen V GordonAbstract:We report an update to the reference genome of the bovine tuberculosis bacillus Mycobacterium bovis AF2122/97 generated using an integrative multi-omics approach. Updates include 42 new CDS, 14 modified annotations, 26 SNP corrections, and disclosure that the RD900 locus, previously described as absent from the genome, is in fact present.
-
bottlenecks and broomsticks the molecular evolution of Mycobacterium bovis
Nature Reviews Microbiology, 2006Co-Authors: Noel H Smith, Stephen V Gordon, Ricardo De La Ruadomenech, R S Cliftonhadley, Glyn R HewinsonAbstract:Mycobacterium bovis is the cause of tuberculosis in cattle and is a member of the Mycobacterium tuberculosis complex. In contrast to many other pathogenic bacterial species, there is little evidence for the transfer and recombination of genes between cells. The clonality of this group of organisms indicates that the population structure is dominated by reductions in diversity, caused either by population bottlenecks or selective sweeps as entire chromosomes become fixed in the population. We describe how these forces have shaped not only the phylogeny of this group but also, at a very local level, the population structure of Mycobacterium bovis in the British Isles. We also discuss the practical implications of applying this knowledge to understanding the spread of infection and the development of improved vaccines and diagnostic tests
-
Bottlenecks and broomsticks: the molecular evolution of Mycobacterium bovis
Nature Reviews Microbiology, 2006Co-Authors: Noel H Smith, Stephen V Gordon, Ricardo De La Rua-domenech, Richard S. Clifton-hadley, R. Glyn HewinsonAbstract:The M. tuberculosis complex (with the exception of M. canettii ) shows little evidence for the transfer and recombination of chromosomal genes. We discuss the remarkable consequences of this strict clonality, and show how selective sweeps and population bottlenecks can profoundly reduce the diversity of the population. The clonality of this group of organisms has shaped the phylogeny of the M. tuberculosis complex and we suggest that they might best be described as a group of host-adapted ecotypes rather than species. Our analysis highlights the close sequence similarity of these ecotypes and the facility these organisms have for invading and establishing themselves in new mammalian hosts. The history and molecular epidemiology of bovine tuberculosis in the British Isles is then reviewed. A test and slaughter programme was initially highly successful at reducing the incidence of disease but, since the 1980s (and in contrast to the rest of Europe), has failed to control an exponential increase in incidents. The molecular epidemiology of bovine tuberculosis reveals that a single clonal complex of strains has come to dominate throughout the British Isles and is responsible for over 85% of the bovine tuberculosis in Great Britain. We suggest that the limited diversity of M. bovis in the British Isles is a result of a population bottleneck induced by more than 100 years of bovine tuberculosis control programmes, in particular the extensive test and slaughter regime. The recent dominance and exponential increase of a single clonal complex can best be explained by selection, and two possible selective advantages of the dominant clonal complex in the British Isles are discussed. Finally, we show how an understanding of the population structure and molecular epidemiology of this disease has contributed to our appreciation of the role of cattle movement and badgers in the spread and maintenance of the disease, and we describe the practical application to the development of advanced techniques of diagnosis and vaccination. Mycobacterium bovis is the cause of tuberculosis in cattle and is a member of the Mycobacterium tuberculosis complex. In contrast to many other pathogenic bacterial species, there is little evidence for the transfer and recombination of genes between cells. The clonality of this group of organisms indicates that the population structure is dominated by reductions in diversity, caused either by population bottlenecks or selective sweeps as entire chromosomes become fixed in the population. We describe how these forces have shaped not only the phylogeny of this group but also, at a very local level, the population structure of Mycobacterium bovis in the British Isles. We also discuss the practical implications of applying this knowledge to understanding the spread of infection and the development of improved vaccines and diagnostic tests. Unlike many other bacterial pathogens, there is little evidence for genetic recombination in the Mycobacterium tuberculosis complex. Smith et al . review how this strict clonality has shaped the phylogeny of the M. tuberculosis complex, focusing on the consequences of clonality for the population structure of Mycobacterium bovis within the British Isles.
Ákos Lantos - One of the best experts on this subject based on the ideXlab platform.
-
pulmonary tuberculosis due to Mycobacterium bovis subsp caprae in captive siberian tiger
Emerging Infectious Diseases, 2003Co-Authors: Ákos Lantos, Stefan Niemann, Endre Sós, Károly Erdélyi, Sándor Dávid, Linda M. Parsons, Tanja Kubica, László Mezõsi, Sabine Ruschgerdes, Akos SomoskoviAbstract:We report the first case of pulmonary tuberculosis caused by Mycobacterium bovis subsp. caprae in a captive Siberian tiger, an endangered feline. The pathogen was isolated from a tracheal aspirate obtained by bronchoscopy. This procedure provided a reliable in vivo diagnostic method in conjunction with conventional and molecular tests for the detection of mycobacteria.
-
Pulmonary Tuberculosis due to Mycobacterium bovis in Captive Siberian Tiger
Centers for Disease Control and Prevention, 2003Co-Authors: Ákos Lantos, Stefan Niemann, László Mezősi, Endre Sós, Károly Erdélyi, Sándor Dávid, Linda M. Parsons, Tanja Kubica, Sabine Rüsch-gerdes, Akos SomoskoviAbstract:We report the first case of pulmonary tuberculosis caused by Mycobacterium bovis subsp. caprae in a captive Siberian tiger, an endangered feline. The pathogen was isolated from a tracheal aspirate obtained by bronchoscopy. This procedure provided a reliable in vivo diagnostic method in conjunction with conventional and molecular tests for the detection of mycobacteria
Fabiana Kömmling Seixas - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer
Applied Microbiology and Biotechnology, 2015Co-Authors: K. R. Begnini, J. H. Buss, T. Collares, Fabiana Kömmling SeixasAbstract:In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette–Guérin (BCG) has been used for treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients. Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer, BCG is ineffective in approximately 30–40 % of cases and disease recurs in up to 50 % of patients. Since that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. Herein, we discuss current advances in recombinant BCG construction, research, concerns, and future directions to promote the development of this promising immunotherapeutic approach for bladder cancer.
-
Recombinant Mycobacterium bovis BCG.
Vaccine, 2009Co-Authors: Reginaldo G. Bastos, Sibele Borsuk, Fabiana Kömmling Seixas, Odir Antônio DellagostinAbstract:The Bacillus Calmette–Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated Mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed.
Odir Antônio Dellagostin - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Mycobacterium bovis BCG.
Vaccine, 2009Co-Authors: Reginaldo G. Bastos, Sibele Borsuk, Fabiana Kömmling Seixas, Odir Antônio DellagostinAbstract:The Bacillus Calmette–Guerin (BCG) is an attenuated strain of Mycobacterium bovis that has been broadly used as a vaccine against human tuberculosis. This live bacterial vaccine is able to establish a persistent infection and induces both cellular and humoral immune responses. The development of mycobacterial genetic systems to express foreign antigens and the adjuvanticity of BCG are the basis of the potential use of this attenuated Mycobacterium as a recombinant vaccine. Over the years, a range of strategies has been developed to allow controlled and stable expression of viral, bacterial and parasite antigens in BCG. Herein, we review the strategies developed to express heterologous antigens in BCG and the immune response elicited by recombinant BCG constructs. In addition, the use of recombinant BCG as an immunomodulator and future perspectives of BCG as a recombinant vaccine vector are discussed.
